TABLE 2

PPI measured with prepulses at 6, 12, and 18 db above the background in C57Bl/6J mice, which received BQCA via the subcutaneous route

Data are presented as means ± S.E.M.

DrugPPI
pp6pp12pp18
%
Vehicle control23.6 ± 3.436.2 ± 3.050.3 ± 2.4
MK-801−3.0 ± 3.2*15.7 ± 3.6*17.4 ± 2.5*
 + 1 mg/kg BQCA1.1 ± 5.112.1 ± 4.717.5 ± 6.8
 + 3 mg/kg BQCA0.8 ± 6.26.9 ± 5.04.6 ± 5.0
 + 10 mg/kg BQCA1.4 ± 5.711.1 ± 6.021.4 ± 6.1
 + 20 mg/kg BQCA−8.0 ± 4.96.2 ± 3.917.9 ± 2.5
MK-801 + 0.25 mg/kg haloperidol4.4 ± 2.022.1 ± 3.537.1 ± 4.4
 + 1 mg/kg BQCA6.2 ± 3.618.8 ± 3.135.6 ± 2.9
 + 3 mg/kg BQCA7.7 ± 2.723.9 ± 4.237.8 ± 5.5
 + 10 mg/kg BQCA10.9 ± 2.923.7 ± 3.536.9 ± 4.4
 + 20 mg/kg BQCA12.9 ± 2.034.4 ± 4.457.8 ± 4.7**
MK-801 + 2 mg/kg clozapine9.4 ± 3.725.7 ± 4.637.9 ± 6.2
 + 1 mg/kg BQCA8.4 ± 2.616.7 ± 2.836.3 ± 4.2
 + 3 mg/kg BQCA3.7 ± 6.012.5 ± 6.827.5 ± 4.9
 + 10 mg/kg BQCA0.2 ± 3.822.4 ± 4.438.0 ± 4.4***
 + 20 mg/kg BQCA14.0 ± 8.032.6 ± 4.756.4 ± 4.9**
MK-801 + 2.5 mg/kg aripiprazole8.2 ± 3.220.7 ± 3.527.7 ± 4.3
 + 1 mg/kg BQCA0.1 ± 3.811.9 ± 5.822.7 ± 6.9
 + 3 mg/kg BQCA−3.6 ± 5.214.4 ± 4.230.3 ± 3.9
 + 10 mg/kg BQCA10.0 ± 2.917.9 ± 3.932.0 ± 4.9
 + 20 mg/kg BQCA3.9 ± 4.526.2 ± 5.247.0 ± 3.1**

  • ↵* P < 0.05 (versus vehicle control − MK-801 effect); **P < 0.001 (versus MK-801 control at the same prepulse); ***P < 0.05 (versus MK-801 control at the same prepulse).